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AbstrACt
Introduction Atopic dermatitis is a complex disease 
with differing clinical presentations. Many attempts have 
been made to identify uniform subtypes, or phenotypes, 
of atopic dermatitis in order to identify different 
aetiologies, improve diagnosis, estimate more accurate 
clinical prognoses, inform treatment andmanagement 
or predict treatment efficacy andeffectiveness. However, 
no consensus yet exists on exactly what defines these 
phenotypes or how many there are and whether they are 
genuine or statistical artefacts. This review aims to identify 
previously reported phenotypes of atopic dermatitis, the 
features used to define them and any characteristics or 
clinical outcomes significantly associated with them.
Methods and analysis We will search Ovid Embase, Ovid 
MEDLINE and Web of Science from inception to the latest 
available date at the time of the search for studies attempting 
to classify atopic dermatitis in humans using any cross-
sectional or longitudinal epidemiological or interventional 
design. Primary outcomes are atopic dermatitis phenotypes, 
features used to define them and characteristics associated 
with them in subsequent analyses. A secondary outcome 
is the methodological approach used to derive them. Two 
reviewers will independently screen titles and abstracts 
for inclusion, extract data and assess study quality. We will 
present the results of this review descriptively and with 
frequencies where possible.
Ethics and dissemination Ethical approval is not 
required for this study as it is a systematic review. We 
will report results from this systematic review in a peer-
reviewed journal. The main value of this study will be to 
inform further research.
PrOsPErO registration number CRD42018087500
IntrOduCtIOn
Atopic dermatitis, also known as atopic 
eczema, eczema, neurodermatitis and Besni-
er’s prurigo,1 2 is a complex disease with vari-
able clinical presentations, associations with 
other atopic diseases and clinical courses.3 
Traditionally, atopic dermatitis was character-
ised as an allergic disease of childhood, but it 
is now well-established that non-allergic forms 
exist and patients have been subdivided into 
those with and without atopy. However, there 
is much evidence suggesting that this dichot-
omisation is not clinically useful4; despite 
the use of names such as ‘atopic derma-
titis’ or ‘atopic eczema’, up to two-thirds of 
patients with the disease are not atopic and 
atopy status does not predict outcomes or 
treatment responses.5 Furthermore, genetic 
research in the last decade has led to a para-
digm shift in understanding the aetiology 
of atopic dermatitis, from being considered 
primarily an allergic/immunological disorder 
to understanding the additional importance 
of skin barrier dysfunction.6 7 Recent ‘-omics’ 
research has further highlighted a role of lipid 
composition and immune pathways in disease 
pathology and phenotypic presentation.8–10 
A phenotype is sometimes defined as a set 
of observable characteristics of an individual 
resulting from the interaction of its geno-
type with the environment.11 This includes, 
for example, the individual’s clinical charac-
teristics, development and behaviour. In an 
epidemiological context, the word phenotype 
additionally refers to subtypes of a disease 
that are defined by different phenotypic 
strengths and limitations of this study
 ► Prospectively registered review reported consis-
tent with Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines.
 ► This study will provide the first comprehensive re-
view of current evidence on phenotypic subgroup-
ings of atopic dermatitis. This is an important topic 
in a time of rapid development of new therapeutic 
options.
 ► It will be difficult to assess bias resulting from non-pub-
lication of studies or selective reporting of results.
 ► It may be difficult to synthesise the results, due to 
expected heterogeneity in identified phenotypes and 
in the outcomes/other characteristics explored.
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appearances. These subtypes may be referred to using 
a variety of terminology in addition to ‘phenotypes’: 
for example, they may be called disease classifications, 
subgroups, typologies, strata, patterns or taxonomies by 
different researchers. Subtypes or phenotypes are not 
to be confused with endotypes, which are subtypes of a 
disease defined specifically by different functional or 
pathobiological mechanisms. One endotype could give 
rise to multiple phenotypes.
Current atopic dermatitis phenotypes are based on clin-
ical (exogenous) features, measurable genetic or immu-
nological (endogenous) features, comorbidities or signs 
or symptoms course. In general, study participants have 
been characterised by a particular external character-
istic, for example, history of eczema herpeticum (some-
times called an exophenotype) or internal characteristic, 
for example, elevated serum IgE, or low filaggrin protein 
expression or Th17 activation in skin (endophenotypes). 
Clinical comorbidities (such as asthma and hay fever or 
ichthyosis) and symptom trajectories have also been used 
to define phenotypes.12–15 Recent studies have highlighted 
the heterogeneity of signs and symptoms trajectories and 
have suggested that different clinical courses are associated 
with immunological characteristics, disease locations and 
comorbidities such as food allergy.16 17
If there exist a number of atopic dermatitis phenotypes, 
each of which exhibits homogeneous disease characteris-
tics, this has the potential to inform aetiology (ie, identify 
endotypes), patient prognosis and prediction of treatment 
efficacy. Finding simple, meaningful disease phenotypes 
can elucidate the different biological pathways underpin-
ning them, leading to the discovery of endotypes (aeti-
ology); knowledge of the markers for these pathways can 
assist clinicians in diagnosing and managing patients’ symp-
toms more accurately, particularly on whether to expect 
persistence or remission (prognosis) and whether a poten-
tial treatment will work for them (prediction). At present, 
treatment for long-term atopic dermatitis is not based on 
disease phenotypes; treatment is symptomatic and may 
have associated toxicity.18 The identification of meaningful 
phenotypes has potential to improve treatment strategies 
and provide biological insights into the future development 
of new ones.
No study has systematically reviewed the literature 
summarising the currently existing phenotypic classifica-
tions of atopic dermatitis. We will do this, aiming to iden-
tify previously reported phenotypes in studies specifically 
designed to identify subtypes of atopic dermatitis. We will 
also describe the features used to define them and whether 
they were predictive of or associated with any outcomes, 
concurrent conditions, treatment response or other rele-
vant variables.
MEthOds And AnAlysIs
Eligibility criteria
We will search for studies with any cross-sectional or longi-
tudinal epidemiological or interventional design whose 
primary or secondary aim is to define or identify subtypes/
classifications/phenotypes of atopic dermatitis in humans 
of any age and gender. Features used to identify pheno-
types could be based on either static or dynamic character-
istics of their populations, and could include any feature 
of the disease, including clinical presentation, and genetic, 
immunological or molecular characteristics. We expect 
that most studies will contain only individuals with atopic 
dermatitis but some studies may have included individuals 
without it, for example, as a negative control group15 or 
because a formal diagnosis was unavailable. We will include 
these studies. If included, the control population would be 
people known to be free of atopic dermatitis or who have a 
low probability of having it, including people who may have 
asthma, hay fever and other atopic diseases.
We will exclude: studies of localised eczema such as hand 
eczema and other types of eczema such as contact derma-
titis and adult seborrheic dermatitis (for studies prior to 
1990, we may include seborrheic dermatitis during infancy); 
literature reviews, books, book chapters, case reports, case 
series and in-progress phenotyping studies (abstracts), but 
not ongoing birth or other cohort studies; and conference 
proceedings and abstracts, as they are unlikely to provide 
sufficient detail on the definitions of atopic dermatitis 
phenotypes.
Information sources
We will search Ovid Embase, Ovid MEDLINE and Web of 
Science from inception to the latest available date at the 
time of the search for publications in any language using 
English search terms. We will limit results to human studies 
published in original journal articles (published or in press, 
excluding retracted articles). We will interrogate the refer-
ence lists from the most recent two major review articles in 
each database.
search strategy
We will use conduct the following MEDLINE search:
((exp phenotype/OR classification OR sub?type OR 
phenotyp* OR taxonomy OR disease type* OR disease 
typolog* OR stratif* OR strata) AND (exp dermatitis, 
atopic/OR exp eczema/OR exp neurodermatitis/OR 
eczema* OR atopic dermatitis OR neurodermatitis OR 
besnier* prurigo))
Searches for the other databases will be matched as 
closely as possible to this using appropriate syntax and 
headings.
study records
Data management
Literature search results will be uploaded to Covidence 
web software, which will be used for all stages of the 
review process including title/abstract screening, full-text 
screening, data extraction, bias/quality assessment and 
process flow capture. We will develop and test screening 
questions based on the inclusion and exclusion criteria and 
a data extraction form based on the outcomes and pilot 
them on a subset of studies.
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Selection process
Two reviewers will scan all titles and abstracts independently. 
Publications that both reviewers record as ‘not relevant’ will 
not be retrieved for full-text review; the full text of all others 
will be retrieved into a ‘short-list’.
Publications will be automatically included in this study 
if both reviewers independently assess them as meeting the 
inclusion criteria and excluded from this study where both 
assess them as not meeting the criteria. Disagreements will 
be resolved through referral to a third reviewer.
Data collection process
During the short-list review, data from the texts in full will 
be extracted by two reviewers using a predesigned data 
extraction form and disagreements will be resolved by 
discussion among investigators.
data items
We will extract three domains of data from publications 
included in our study. In the event of subgroup analyses, 
such as studies reporting different atopic dermatitis pheno-
types for men and women, we will extract data from the 
combined-group phenotypes if available. If unavailable, we 
will extract data for each phenotype separately. We believe 
it unlikely that more than one subgroup analysis will have 
been conducted in the absence of a main single analysis, but 
if this happens, we will extract data from the first subgroups 
reported in the Results section of the paper.
Study data
We will extract the following items relating to the study: 
design, year(s) conducted, country/countries conducted 
in, setting conducted in (population-based, specialist 
etc), inclusion/exclusion criteria, number of participants, 
age range of participants, gender balance of participants, 
notable comorbidities (from study design) including, 
for example, proportions with other atopic diseases.
Disease data
We will extract the following items relating to atopic 
dermatitis: definition codes/criteria, severity definition, 
prevalence and incidence (if relevant).
Outcomes
We will extract the following items relating to atopic 
dermatitis phenotypes: a qualitative description of the 
phenotypes, features (variables) used to define pheno-
types, age at the time of phenotype definition, proportion 
of individuals in each phenotype, qualitative description 
of any variables statistically significantly associated (in 
subsequent analyses) with the phenotypes (we will not 
report the effect estimates), statistical or other method 
used for classification, whether controls were used in clas-
sification algorithm.
Outcomes and prioritisation
The outcomes for this review are atopic dermatitis pheno-
types and associated characteristics, all of which are qual-
itative (ie, non-numeric) data.
Primary outcomes are: (1) atopic dermatitis pheno-
types reported in published papers; (2) the features used 
to define the phenotypes (ie, the ‘exposure’ variables); 
and (3) the characteristics statistically significantly associ-
ated (in subsequent analyses) with the phenotypes, if any, 
which could include: long-term clinical outcomes such 
as disease persistence or severity; concurrent conditions 
such as other atopic disease; treatment response; genetic 
data (eg, FLG mutations); or any other variables reported 
in studies. 
Our secondary outcome is a brief summary of the meth-
odological approaches used to derive atopic dermatitis 
phenotypes. 
We will not proactively seek particular values of the 
outcomes described above; we will collect any and all 
outcomes reported in the publications.
risk of bias
We will assess quality within and between studies using 
a checklist modified from the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) 
tool19 for clinical trials or observational studies. Where 
relevant, instead of effect estimates and confidence inter-
vals, we will assess equivalent parameters for the methods 
used to derive subtypes. We will additionally consider 
upgrading the final assessment by one level if the study 
is prospective, population-based or has been replicated.
Within studies
We will treat the exposure as the feature(s) used to iden-
tify phenotypes, which will vary between studies, and the 
outcome as the identified phenotypes. We will give an 
initial rating of ‘high quality’ for randomised controlled 
trials or ‘low quality’ for observational studies and then 
judge risk of bias based on the extracted information on 
each of the domains relevant to the study type. Each item 
will be rated ‘high risk of bias’ or ‘low risk of bias’ and will 
be synthesised according to GRADE recommendations. 
Based on the synthesised judgement we will consider 
whether to downgrade or upgrade the initial quality 
assessment. Final possible quality assessments for indi-
vidual studies are ‘high’, ‘moderate’, ‘low’ and ‘very low’.
Between studies
We anticipate the phenotype descriptions to vary between 
studies according to the features used to define them 
(exposure variables), so for a given outcome, it may not 
be possible to synthesise across studies. However, where 
it is possible, we will synthesise study results according to 
GRADE recommendations. Final possible quality assess-
ments for the body of evidence are ‘high’, ‘moderate’ and 
‘low’.
data synthesis
The nature of the outcomes for this review precludes 
quantitative synthesis, so we will report our findings 
narratively. Our primary outcomes (atopic dermatitis 
phenotypes, the features used to define them and the 
outcomes/characteristics associated with them) are all 
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qualitative and we expect them to differ between studies, 
but where possible, we will group them into sensible cate-
gories and report frequencies.
For our secondary outcome, we will report the type and 
frequency of methodological approach used to derive the 
phenotypes.
We expect heterogeneity in all our outcomes because 
we have no reason to expect studies will have used similar 
protocols to explore phenotypes: for example, studies will 
probably have used different exposure variables to define 
phenotypes and will represent populations of people with 
different characteristics. To explore, this we will compare 
the: participant age and gender balance, study design, 
World Health Organization (WHO) region (Africa, 
Americas, Southeast Asia, Europe, Eastern Mediterra-
nean and Western Pacific) and disease definition for each 
study, where possible. We will also look at hospital-based 
and population-based studies separately.
Meta-biases
Outcomes in this review may be prone to meta-bias 
resulting from an absence of studies looking at important 
indicators of phenotypes, non-publication of study results 
or selective reporting of outcomes. For our qualitative 
outcomes, it will not be possible to measure this objec-
tively. We will speculate on whether this is likely to be an 
important limiting factor in interpreting our results.
Patient and public involvement
The research questions have been developed in consulta-
tion with Dr Sinéad Langan’s Senior Clinical fellowship 
steering committee, which includes patient representa-
tion. The authors would like to thank Amanda Roberts 
for her contributions to discussions.
EthICs And dIssEMInAtIOn
This systematic review protocol was registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO) on 31 January 2018 and was last updated 
on 5 July 2018. Any amendments to the protocol will be 
documented on the PROSPERO site contemporaneously, 
with full explanation of any change. Ethical approval is 
not required for this study as it is a systematic review. We 
plan to submit a report of our findings for publication 
in a peer-reviewed journal. Findings from the report will 
also support the first author’s PhD thesis.
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